Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 13, 2018 08:00 ET | Source: Delcath Systems, Inc.

Delcath Reminds Shareholders that the Rights Offering Subscription Period Expires Wednesday, September 26, 2018

NEW YORK, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds its...
September 04, 2018 08:00 ET | Source: Delcath Systems, Inc.

Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC to be Published in European Radiology

NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
August 28, 2018 08:33 ET | Source: Delcath Systems, Inc.

Delcath Announces Extension of Rights Offering Period to September 26, 2018

NEW YORK, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that...
August 27, 2018 09:00 ET | Source: Delcath Systems, Inc.

Delcath Announces Acceptance of Abstract for Poster Presentation at CIRSE 2018

NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
August 23, 2018 11:14 ET | Source: Delcath Systems, Inc.

Delcath Announces 3rd Independent Safety Review of Randomized Trial Data for Metastatic Ocular Melanoma; Recommended Continuation with no Trial Modification

NEW YORK, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
August 22, 2018 09:41 ET | Source: Delcath Systems, Inc.

Delcath Announces Pending Expiration to Rights Offering Subscription Period

NEW YORK, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds its...
August 21, 2018 08:52 ET | Source: Delcath Systems, Inc.

First Patient Enrolled in Delcath Amended Registration Trial in Metastatic Ocular Melanoma

NEW YORK, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
August 20, 2018 08:00 ET | Source: Delcath Systems, Inc.

Delcath Announces Beginning of Enrollment of Amended Metastatic Ocular Melanoma Registration Trial

NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
August 17, 2018 08:00 ET | Source: Delcath Systems, Inc.

Delcath Issues Letter to Stockholders

NEW YORK, Aug. 17, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH) (“Delcath” or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic...
August 15, 2018 08:00 ET | Source: Delcath Systems, Inc.

Delcath Announces Second Quarter Fiscal 2018 Financial Results

NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right